CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...
PharmiWeb1d
Formycon receives positive CHMP opinion for FYB203…
Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...
sanofi4d
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in ...
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce ...
PharmiWeb22h
Update on Financial Position
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, wishes to provide an update on its ...
NurExone Biologic Inc: NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based ...
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Le Lézard4d
The Launch Of Qualia Magnesium+ Sets New Standard In How Magnesium Can Be Supplemented
There is clear agreement in the scientific community that magnesium is crucial to human health, supporting everything from bone and heart health to sleep quality and muscle recovery. Yet many studies, ...
pharmaphorum1d
European Health Data Space (EHDS) update: what this means for pharmaceutical and biotech
The proposed EHDS Regulation 1 (Proposal), introduced ... to ensure high levels of quality and safety of health care, medicinal products, or devices; training, testing, and evaluating of ...
clinicaltrialsarena6d
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy
Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
manilatimes6d
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
MIPLYFFA was further granted Orphan Medicinal Product designation by the European Medicines Agency (EMA ... Participation in these programs is subject to the laws and regulations of each jurisdiction ...